Patents by Inventor Makiko Nakayama
Makiko Nakayama has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11952423Abstract: A novel antibody that can be used as an anti-tumor agent and an anti-tumor agent that comprises, as an active ingredient, a molecule containing such an antibody.Type: GrantFiled: May 16, 2023Date of Patent: April 9, 2024Assignees: MIE UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITEDInventors: Hiroshi Shiku, Yasushi Akahori, Kento Tanaka, Ayaka Yatsu, Junya Ichikawa, Toshiaki Ohtsuka, Shiho Kozuma, Ryuji Hashimoto, Makiko Nakayama, Naoya Shinozaki, Kensuke Nakamura, Ichiro Watanabe, Shinji Furuzono
-
Publication number: 20230348616Abstract: An antibody that can be used as an anti-tumor agent and an anti-tumor agent comprises a molecule containing such an antibody. Such an antibody or a binding fragment thereof comprises: a heavy chain CDRH1 consisting of SEQ ID NO: 54, a heavy chain CDRH2 consisting of SEQ ID NO: 55, a heavy chain CDRH3 consisting of SEQ ID NO: 56, a light chain CDRL1 consisting of SEQ ID NO: 57 or a light chain CDRL1 consisting of an amino acid sequence derived from SEQ ID NO: 57 in which amino acid 7 is W and/or amino acid 8 is K, a light chain CDRL2 consisting of SEQ ID NO: 58, and a light chain CDRL3 consisting of SEQ ID NO: 59 or a light chain CDRL3 consisting of an amino acid sequence derived from SEQ ID NO: 59 in which amino acid 2 is A or S.Type: ApplicationFiled: March 29, 2021Publication date: November 2, 2023Applicants: MIE UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITEDInventors: Hiroshi SHIKU, Yasushi AKAHORI, Kento TANAKA, Ayaka YATSU, Junya ICHIKAWA, Toshiaki OHTSUKA, Shiho KOZUMA, Ryuji HASHIMOTO, Makiko NAKAYAMA, Naoya SHINOZAKI, Kensuke NAKAMURA, Ichiro WATANABE, Shinji FURUZONO
-
Publication number: 20230287121Abstract: A novel antibody that can be used as an anti-tumor agent and an anti-tumor agent that comprises, as an active ingredient, a molecule containing such an antibody.Type: ApplicationFiled: May 16, 2023Publication date: September 14, 2023Applicants: MIE UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITEDInventors: Hiroshi SHIKU, Yasushi AKAHORI, Kento TANAKA, Ayaka YATSU, Junya ICHIKAWA, Toshiaki OHTSUKA, Shiho OKZUMA, Ryuji HASHIMOTO, Makiko NAKAYAMA, Naoya SHINOZAKI, Kensuke NAKAMURA, Ichiro WATANABE, Shinji FURUZONO
-
Patent number: 9822722Abstract: The fuel pressure sensor abnormality diagnosis apparatus diagnoses that a fuel pressure sensor is abnormal in the case where, because a state where a detected value of the fuel pressure sensor is less than a target value occurs, a fuel discharge amount of a fuel pump is increased, and as a result, the fuel discharge amount reaches its maximum amount, and even if a predetermined period has elapsed since the fuel discharge amount reaches its maximum amount, the detected value is less than the target value.Type: GrantFiled: September 23, 2015Date of Patent: November 21, 2017Assignee: TOYOTA JIDOSHA KABUSHIKI KAISHAInventors: Shunichi Tsutsuji, Koji Honda, Makiko Nakayama, Kinji Morihiro
-
Patent number: 9751944Abstract: Provided is a pharmaceutical composition for treating and/or preventing abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.Type: GrantFiled: June 5, 2015Date of Patent: September 5, 2017Assignee: Daiichi Sankyo Company, LimitedInventors: Yoshiharu Hiruma, Eisuke Tsuda, Takeshi Takizawa, Makiko Nakayama
-
Publication number: 20160090933Abstract: The fuel pressure sensor abnormality diagnosis apparatus diagnoses that a fuel pressure sensor is abnormal in the case where, because a state where a detected value of the fuel pressure sensor is less than a target value occurs, a fuel discharge amount of a fuel pump is increased, and as a result, the fuel discharge amount reaches its maximum amount, and even if a predetermined period has elapsed since the fuel discharge amount reaches its maximum amount, the detected value is less than the target value.Type: ApplicationFiled: September 23, 2015Publication date: March 31, 2016Applicant: TOYOTA JIDOSHA KABUSHIKI KAISHAInventors: Shunichi TSUTSUJI, Koji Honda, Makiko Nakayama, Kinji Morihiro
-
Publication number: 20150299318Abstract: Provided is a pharmaceutical composition for treating and/or preventing abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.Type: ApplicationFiled: June 5, 2015Publication date: October 22, 2015Applicant: Daiichi Sankyo Company, LimitedInventors: Yoshiharu Hiruma, Eisuke Tsuda, Takeshi Takizawa, Makiko Nakayama
-
Patent number: 9079959Abstract: Provided is a pharmaceutical composition for treating and/or preventing abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.Type: GrantFiled: September 30, 2013Date of Patent: July 14, 2015Assignee: Daiichi Sankyo Company, LimitedInventors: Yoshiharu Hiruma, Eisuke Tsuda, Takeshi Takizawa, Makiko Nakayama
-
Patent number: 8987226Abstract: It is intended to provide a polynucleotide that is resistant to RNase and has an RNA interference effect, etc. The present invention provides a single-stranded polynucleotide that is derived from a double-stranded polynucleotide comprising a sense strand polynucleotide corresponding to a target gene, and an antisense strand polynucleotide having a nucleotide sequence complementary to the sense strand polynucleotide, and has a structure in which the 5?-end of the antisense strand and the 3?-end of the sense strand are linked via a phenyl group-containing linker to form a phosphodiester structure at each of these ends.Type: GrantFiled: December 1, 2011Date of Patent: March 24, 2015Assignee: Daiichi Sankyo Company, LimitedInventors: Makoto Koizumi, Yasuhide Hirota, Makiko Nakayama, Mika Ikeda
-
Publication number: 20140065146Abstract: Provided is a pharmaceutical composition for treating and/or preventing abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.Type: ApplicationFiled: September 30, 2013Publication date: March 6, 2014Applicant: Daiichi Sankyo Company, LimitedInventors: Yoshiharu Hiruma, Eisuke Tsuda, Takeshi Takizawa, Makiko Nakayama
-
Patent number: 8575316Abstract: Provided is a pharmaceutical composition for treating and/or preventing abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.Type: GrantFiled: April 7, 2010Date of Patent: November 5, 2013Assignee: Daiichi Sankyo Company, LimitedInventors: Yoshiharu Hiruma, Eisuke Tsuda, Takeshi Takizawa, Makiko Nakayama
-
Publication number: 20130253038Abstract: It is intended to provide a polynucleotide that is resistant to RNase and has an RNA interference effect, etc. The present invention provides a single-stranded polynucleotide that is derived from a double-stranded polynucleotide comprising a sense strand polynucleotide corresponding to a target gene, and an antisense strand polynucleotide having a nucleotide sequence complementary to the sense strand polynucleotide, and has a structure in which the 5?-end of the antisense strand and the 3?-end of the sense strand are linked via a phenyl group-containing linker to form a phosphodiester structure at each of these ends.Type: ApplicationFiled: December 1, 2011Publication date: September 26, 2013Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Makoto Koizumi, Yasuhide Hirota, Makiko Nakayama, Mika Ikeda
-
Publication number: 20110268733Abstract: Provided is a pharmaceutical composition for treating and/or preventing abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.Type: ApplicationFiled: April 7, 2010Publication date: November 3, 2011Inventors: Yoshiharu Hiruma, Eisuke Tsuda, Takeshi Takizawa, Makiko NaKayama
-
Patent number: 7323442Abstract: The present invention provides agents for alleviating symptoms resulting from inflammation, which have an activity to alleviate inflammatory symptoms caused by bacterial infection, particularly accumulation of body fluid such as bronchocavemous plasma exudation, ascites, etc., at the inflammatory site, or excessive increase of blood neutrophils; symptoms resulting from inflammation caused by bacterial infection, particularly accumulation of body fluid such as bronchocavemous plasma exudation ascites, etc., at the inflammatory site, or excessive increase of blood neutrophils, can be alleviated effectively by ingesting or administering orally or parenterally a composition containing human-type lactoferrin as an effective component.Type: GrantFiled: February 13, 2002Date of Patent: January 29, 2008Assignee: Meiji Dairies CorporationInventors: Masako Yajima, Makiko Nakayama, Yumi Tsukamoto, Kaoru Koide, Tamotsu Kuwata, Takaji Yajima
-
Publication number: 20020111295Abstract: The present invention provides agents for alleviating symptoms resulting from inflammation, which have an activity to alleviate inflammatory symptoms caused by bacterial infection, particularly accumulation of body fluid such as bronchocavernous plasma exudation, ascites, etc., at the inflammatory site, or excessive increase of blood neutrophils; symptoms resulting from inflammation caused by bacterial infection, particularly accumulation of body fluid such as bronchocavernous plasma exudation ascites, etc., at the inflammatory site, or excessive increase of blood neutrophils, can be alleviated effectively by ingesting or administering orally or parenterally a composition containing human-type lactoferrin as an effective component.Type: ApplicationFiled: February 13, 2002Publication date: August 15, 2002Applicant: MEIJI DAIRIES CORPORATIONInventors: Masako Yajima, Makiko Nakayama, Yumi Tsukamoto, Kaoru Koide, Tamotsu Kuwata, Takaji Yajima